Non-Hodgkin Lymphoma | Specialty

Biology of Mantle Cell Lymphoma

July 26th 2017

Mantle Cell Lymphoma: Evolution of Therapy

July 26th 2017

Axicabtagene Ciloleucel Emerges as Potential Standard for Some NHL Patients

July 25th 2017

Sattva S. Neelapu, MD, discusses the latest results for axicabtagene ciloleucel (KTE-C19) for transplant-ineligible patients with relapsed/refractory non-Hodgkin lymphoma and the CAR T-cell therapy’s potential to be a new standard of care.

Expert Discusses Pembrolizumab Plus Rituximab in Follicular Lymphoma

July 25th 2017

Loretta Nastoupil, MD, discusses the positive interim analysis and shared her thoughts on areas of future investigation for patients with relapsed follicular lymphoma.

Frontline Obinutuzumab Recommended for EU Approval for Follicular Lymphoma

July 21st 2017

The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of obinutuzumab in the frontline setting for the treatment of patients with follicular lymphoma.

Dr. Matasar on Antibody-Drug Conjugates in B-Cell Malignancies

July 14th 2017

Matthew J. Matasar, MD, attending physician, Memorial Sloan Kettering Cancer Center, discusses antibody drug conjugates in B-cell malignancies.

Dr. Tilly Discusses Study of POLA-R-CHP in DLBCL

July 12th 2017

Herve Tilly, MD, PhD, Centre Henri Becquerel, discusses a study of polatuzumab vedotin combined with rituximab (Rituxan), cyclophosphamide, doxorubicin and prednisone (PLOA-R-CHP) in patients with previously untreated diffuse large B-cell lymphoma.

Dr. Yang on the Efficacy of Immunotherapy in Follicular Lymphoma

July 5th 2017

Zhi Zhang Yang, MD, assistant professor of Medicine, Mayo Clinic, discusses the expression of LAG-3 defining exhaustion of intratumoral PD-1 antibodies and T cells and correlates poor outcomes in patients with follicular lymphoma.

Clinical Trials Exploring Novel Options for T-Cell Lymphoma

June 28th 2017

Jia Ruan, MD, PhD, discusses some of the ongoing work in the field of T-cell lymphoma and the unanswered questions investigators are still facing for these patients

Dr. Hamlin on Results of Cerdulatinib in CLL, Follicular Lymphoma and T-Cell Lymphoma

June 28th 2017

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses results of cerdulatinib in chronic lymphocytic leukemia (CLL), follicular lymphoma and T-cell lymphoma.

Combination of Obinutuzumab and CC-122 Demonstrates Response in R/R Non-Hodgkin Lymphoma

June 25th 2017

The combination of obinutuzumab and CC-122 was well tolerated and demonstrated promising response rates and durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma.

Polatuzumab Vedotin Demonstrates Durable Reponses in Follicular Lymphoma, DLBCL

June 25th 2017

Matthew J. Matasar, MD, discusses the potential of polatuzumab vedotin in patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma.

Cerdulatinib Shows Promise in Relapsed/Refractory NHL

June 24th 2017

Paul A. Hamlin, MD, discusses his research with cerdulatinib in patients with certain types of non-Hodgkin lymphoma.

Dr. Hiddemann on Updated Results of Immunochemotherapy Study in Follicular Lymphoma

June 24th 2017

Wolfgang Hiddemann, MD, PhD, director of the Department of Hematology and Oncology, University of Munich, discusses the updated results of an immunochemotherapy study in follicular lymphoma.

Dr. Hamlin on Study of Cerdulatinib in Non-Hodgkin Lymphoma

June 24th 2017

Paul A. Hamlin, MD, chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center, discusses a study of cerdulatinib in non-Hodgkin lymphoma.

FDA Approves Subcutaneous Rituximab for Blood Cancers

June 22nd 2017

The FDA has approved subcutaneous rituximab (Rituxan Hycela) for the treatment of adults with previously untreated and relapsed or refractory follicular lymphoma, previously untreated diffuse large B-cell lymphoma, and previously untreated and previously treated chronic lymphocytic leukemia.

Dr. Ansell on FDA Approval of Subcutaneous Rituximab in Select Blood Cancers

June 22nd 2017

Stephen M. Ansell, MD, PhD, professor of medicine, Mayo Clinic, discusses the FDA approval of subcutaneous rituximab (Rituxan) in patients with select hematologic malignancies.

Expert Sheds Light on Lesser-Known T-Cell Lymphoma Subtypes

June 22nd 2017

Adrienne A. Phillips, MD, discussed the subtypes of adult T-cell lymphoma/leukemia, the challenges with treating them, and what community oncologists need to know about these patient populations.

FDA Approval Sought for Brentuximab Vedotin in CTCL

June 21st 2017

A supplemental Biologics License Application has been submitted to the FDA for brentuximab vedotin (Adcetris) as a treatment for patients with cutaneous T-cell lymphoma (CTCL), according to Seattle Genetics, which codevelops the antibody-drug conjugate with Takeda.

Rituximab/Lenalidomide Combo Shows Promise for Indolent Lymphomas

June 20th 2017

Treatment with rituximab (Rituxan) plus lenalidomide (Revlimid) followed by maintenance therapy demonstrated promising clinical activity for patients with relapsed/refractory indolent non-Hodgkin's lymphoma, according to findings from the phase IIIb MAGNIFY study.